Tag:
Henri Termeer
Latest Headlines
Latest Headlines
Termeer participates in $20M round for NanoString
Seattle-based NanoString Technologies has closed $20 million in a Series D round of equity financing. New investors include GE, BioMed Ventures and former Genzyme CEO Henri Termeer ( photo ). All
Ex-Genzyme CEO Termeer, GE back translational tech with $20M round
Henri Termeer may have retired from Genzyme after the Sanofi buyout, but he hasn't lost his appetite for betting on promising new technologies for the life sciences field. This morning Seattle-based
Ex-Genzyme chief's $10M gift kicks off MGH cancer center
Biotech pioneer Henri Termeer ( photo ) can now add a startup to his resume. After recently retiring from Genzyme in the wake of the big Sanofi ( $SNY ) buyout, Termeer is seeding the Henri and Belinda
Termeer launches cancer research center with $10M in seed cash
Biotech pioneer Henri Termeer can now add a startup to his resume. After recently retiring from Genzyme in the wake of the big Sanofi buyout, Termeer is seeding the Henri and Belinda Termeer Center
Verastem snags $32M for drugs against cancer stem cells
The young field of cancer stem cells has some new financial firepower behind it. Start-up Verastem has closed a $32 million Series B round of financing with plans to advance its first drug against
Viehbacher: Emerging markets, yes, but U.S., too
All eyes were on Sanofi-Aventis ( $SNY ) chief Christopher Viehbacher ( photo ) and Genzyme ( $GENZ ) CEO Henri Termeer ( photo ) at J.P. Morgan's healthcare conference, looking for clues to the status of
Report: Termeer's value hunt yields buyout interest
The Genzyme ( $GENZ ) headline today focuses on possible buyout interest from Takeda Pharmaceutical Industries. Is the Japanese drugmaker really interested in paying up to $20 billion for the
Sanofi $69 offer hits Termeer's personal wallet
Genzyme CEO Henri Termeer ( photo ) may have a selfish reason for refusing Sanofi-Aventis' $69-per-share offer. Yes, Termeer would get a big buyout bonus--$11 million by some estimates--but that bonus
Frustrated Sanofi takes bid to Genzyme shareholders
Sanofi-Aventis got tired of waiting. The French drugmaker has gone hostile with its $18.5 billion bid for Genzyme, hoping to gain more traction with shareholders than it did with management. As Cowen
Sanofi shops for more Genzyme financing
Word on the street is that Sanofi-Aventis has been lining up more financing to boost its $18.5 billion bid for Genzyme. The Wall Street Journal reports that Sanofi--which already has secured
